Toxic shock syndrome primary prevention
|
Toxic shock syndrome Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Toxic shock syndrome primary prevention On the Web |
|
American Roentgen Ray Society Images of Toxic shock syndrome primary prevention |
|
Risk calculators and risk factors for Toxic shock syndrome primary prevention |
Please help WikiDoc by adding more content here. It's easy! Click here to learn about editing.
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Menstrual toxic shock syndrome can be prevented by avoiding the use of highly absorbent tampons. Risk can be reduced by changing tampons more frequently and using tampons only once in a while during menstruation.
- Women can prevent menstrual-related toxic shock syndrome by not using tampons, especially the superabsorbent variety.
- All wounds should be kept clean and monitored for signs of infection
The spread of all types of group A streptococcal infections can be reduced by good hand washing, especially after coughing and sneezing and before preparing foods or eating.
Patients with confirmed strep throat should stay at home until 24 hours after commencing antibiotic treatment.
All wounds should be kept clean and watched for possible signs of infection such as redness, swelling, drainage, and pain at the wound site.
It is not necessary for all people exposed to someone with an invasive group A streptococcal TSS to receive antibiotic therapy to prevent infection. However, in certain circumstances, antibiotic therapy may be appropriate.
Centers for Disease Control and Prevention. GAS frequently asked questions. May 2014. http://www.cdc.gov (last accessed 9 January 2017)
Avoiding extended tampon use has decreased the incidence of staphylococcal TSS. Lack of seroconversion after an acute staphylococcal illness may be used as a marker for patients at risk for recurrent disease. These patients should be treated for a protracted course with antistaphylococcal antibodies for at least 2 weeks
Experimental staphylococcal vaccines and immunotherapies in clinical trials.
PMCID: PMC3102526